Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
Company profile
Ticker
BZYR
Exchange
Website
CEO
Dr. Stanislaw R. Burzynski M.D., Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
760136810
BZYR stock data
Latest filings (excl ownership)
10-Q
2025 Q2
Quarterly report
10 Oct 24
10-Q
2024 Q1
Quarterly report
15 Jul 24
10-K
2024 FY
Annual report
29 May 24
10-Q
2024 Q3
Quarterly report
16 Jan 24
10-Q
2024 Q2
Quarterly report
12 Oct 23
10-Q
2024 Q1
Quarterly report
13 Jul 23
10-K
2023 FY
Annual report
25 May 23
8-K
Entry into a Material Definitive Agreement
22 May 23
8-K
Departure of Directors or Certain Officers
6 Apr 23
10-Q
2023 Q3
Quarterly report
13 Jan 23
Latest ownership filings
Financial summary
Quarter (USD) | Aug 24 | May 24 | Feb 24 | Nov 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Feb 24 | Feb 23 | Feb 22 | Feb 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.22 k | 1.22 k | 1.22 k | 1.22 k | 1.22 k | 1.22 k |
Cash burn (monthly) | (no burn) | 15.08 | 123.28 k | 128.09 k | 49.37 k | 45.53 k |
Cash used (since last report) | n/a | 25.97 | 212.25 k | 220.54 k | 84.99 k | 78.39 k |
Cash remaining | n/a | 1.19 k | -211.04 k | -219.32 k | -83.78 k | -77.17 k |
Runway (months of cash) | n/a | 78.9 | -1.7 | -1.7 | -1.7 | -1.7 |